title: [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]
abstract: Many patients under oral anticoagulation therapy need percutaneous or surgical interventions/operations. For vitamin K antagonists (VKA), there are recommendations regarding preoperative or postoperative administration. Management of the new oral anticoagulants (NOAC) was supposed to be easier - but some aspects must be considered. Due to the different pharmacokinetic profiles of substances such as dabigatran, rivaroxaban, apixaban, and edoxaban, different recommendations are given.Upon periprocedural management, thromboembolic risk has to be considered in patients treated with NOACs. NOACS have a pharmacokinetic advantage in terms of a rapid onset and rapid elimination via the liver and kidneys. Impaired renal function results in extended half-life of NOACs considerably.Surgical procedures under NOACS can be scheduled at the beginning of next dosing interval or omitted in low/minimal bleeding risk patients, so that only 2-3 NOAC doses are not administered. In patients with moderate and high risk of bleeding, there should be a NOAC break of 24-48 h prior to surgery in order to allow a corresponding decay of the active metabolite. In patients with low/intermediate risk for thromboembolism, no bridging is necessary if the "unprotected" time (NOAC break) is less than 4-5-(7) days. In patients at high risk of thromboembolism, individual consideration must be taken regarding bridging or extended NOAC break. Whether NOACs can be dispensed or bridging is necessary in these patients must be clarified in randomized trials for periprocedural management of NOACs patients.
authors.affiliation: Medizinische Klinik II, Kardiologie, Angiologie, Internistische Intensivmedizin, St. Marien-Krankenhaus, Kampenstr. 51, 57072, Siegen, Deutschland. m.buerke@marienkrankenhaus.com.|Medizinische Klinik, Martin-Luther-Universität, Halle-Saale, Deutschland. m.buerke@marienkrankenhaus.com.
authors.forename: M
authors.initials: M
authors.lastname: Buerke
authors.affiliation: Klinik für Kardiologie und Allgemeine Innere Medizin, Städtisches Klinikum Solingen, Solingen, Deutschland.
authors.forename: H M
authors.initials: HM
authors.lastname: Hoffmeister
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000503:physiopathology / Q000517:prevention & control*; D000069604:Dabigatran / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011728:Pyridones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069552:Rivaroxaban / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013514:Surgical Procedures, Operative; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013923:Thromboembolism / Q000097:blood* / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D014812:Vitamin K; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban
keywords: Atrial fibrillation; Hemorrhage; Surgery; Venous thromboembolism; direct thrombin antagonist Factor Xa inhibitors